Reinventing Harvest Technology: Single-stage chromatography clarification for recombinant protein therapeutic manufacturing

Modern cell culture processes impose a challenge on conventional depth filtration and centrifugation strategies. As cell culture processes are intensified to yield higher cell densities and product titers, the ability to effectively harvest cell culture fluid with the consistency and scalability required can become challenging. High cell concentrations, titers and impurities can lead to filter blockage and consequently large filter areas and/or complex setups.

Our expert presenters and panelists will discuss key strategies to realize simplified and more efficient clarification setups and operations using fiber chromatography.

    The audience will gain insight into:
  • Methods to improve manufacturing production and efficiency for biologics, from cell line development through upstream and downstream processing.
  • How to improve a manufacturing platform that leverages robust cell line development and an intensified cell culture process.
  • Adopting new technologies to master challenging cell culture harvests.
watch now
Watch the webinar on demand
Dr. Tina Lütke Eversloh

Dr. Tina Lütke Eversloh

Senior Process Manager USP Process Science, Rentschler

After more than ten years in academic research, Dr. Lütke-Eversloh changed her focus to industrial biotechnology and started to work at Rentschler Biopharma SE in April 2015. Her role as a Senior Process Manager in the USP Process Science department addresses various issues of upstream processing. These include all aspects in and around bioreactors, from mammalian cell banking to initial downstream purification.

Aaron Almeida

Aaron Almeida

Manager, Manufacturing Process Optimization, Catalent

Aaron Almeida, Ph.D. is a Chemistry and Biologics expert with 13 years guiding projects from basic research through development in biotech industry. Aaron received a PhD at the University of Wisconsin Madison in Chemistry studying the impact of non-natural chemical modifications to the stability and thermodynamics of proteins. From there, he worked at Arrowhead Pharmaceuticals guiding projects focused on peptide and RNA product design and process development for projects from concept inception through clinical GMP manufacturing. Aaron has been with Catalent for 4 1/2 years, initially in downstream process development and now on the manufacturing team, focused on developing data-rich decision-making strategies for platform development and manufacturing process monitoring.

Hendri Tjandra

Hendri Tjandra

Director of Isolation & Purification Development in Biologics Development, Bayer

Hendri started with Bayer Biotech to work on recombinant coagulation protein FVIII in 2001 after working on cell cycle control and gene therapy vectors. In the last ten years, he managed process development and scale-up of antibody therapeutics production at the Berkeley, CA site of BHC. Process transfers, platform harmonization, and evaluations of new technologies are some of his current responsibilities. He received his BS in Biochemistry from UC Davis, and his doctorate in microtubule biology from Purdue University. Following his post-doc stint with Doug Kellogg at UC Santa Cruz where he employed yeast genetics and biochemistry to understand mitotic cell cycle controls, he continued his interests in protein recovery and purification technologies to optimize mAb development and clinical production at Bayer Healthcare.

Alexei Voloshin

Alexei Voloshin

Global Application Development Manager, 3M

Alexei Voloshin is the Global Application Development Manager in the 3M Separation and Purification Sciences Division. He is responsible for developing and managing new applications and bioprocess technology strategy at 3M, and manages Bioprocess industry collaborations around the globe.

Alexei brings more than 15 years of experience in bio-process development, as well as technical, operational, and business knowledge in the biotechnology field.

Before joining 3M, Alexei held various leadership positions in bio-process development at TheraOne, Theranos, and Sutro Biopharma. He has authored a number of publications and presentations dealing with novel bio-processes and their applications to making advanced bio-therapeutics.

Alexei got his Ph.D. in Chemical Engineering from Stanford University and Bachelor of Chemical Engineering and B.S. in Computer Science from University of Minnesota Twin Cities.

Arsalan Arif

arsalan arif

Founder & CEO, Endpoints News

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.